v3.26.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Net Revenue $ 28,136,757 $ 25,804,252 $ 55,935,291 $ 49,238,348
Cost of goods sold 1,981,347 1,937,282 3,904,936 3,772,249
Gross profit 26,155,410 23,866,970 52,030,355 45,466,099
Operating expenses        
Selling, general and administrative 22,601,690 19,634,319 44,483,210 38,763,527
Research and development 1,154,232 1,056,796 1,913,824 2,007,155
Depreciation and amortization [1],[2] 619,111 688,546 1,206,363 1,382,578
Total operating expenses 24,375,033 21,379,661 47,603,397 42,153,260
Operating income 1,780,377 2,487,309 4,426,958 3,312,839
Other income (expense)        
Interest expense (1,810,311) (1,791,568) (3,609,656) (3,108,660)
Share of losses from equity method investments (433,648) (195,482) (896,155) (339,090)
Interest income 53,814 66,772 3,672
Gain (loss) on disposal of property and equipment (1,376) (1,376) 10,932
Total other income (expense) [3] (2,191,521) (1,987,050) (4,440,415) (3,433,146)
Net income (loss) from continuing operations (411,144) 500,259 (13,457) (120,307)
Net income (loss) from discontinued operations (Note 3) (41,720) (2,518,657) 19,196 (5,425,474)
Net income (loss) (452,864) (2,018,398) 5,739 (5,545,781)
Less: Net loss attributable to noncontrolling interest from continuing operations (4,036) (354) (4,242)
Net income (loss) attributable to Sanara MedTech shareholders $ (452,864) $ (2,014,362) $ 6,093 $ (5,541,539)
Net income (loss) per share, basic:        
Continuing operations $ (0.05) $ 0.06 $ (0.01)
Discontinued operations (0.29) (0.63)
Net income (loss) per share of common stock, basic (0.05) (0.23) (0.64)
Net income (loss) per share, diluted:        
Continuing operations (0.05) 0.05 (0.01)
Discontinued operations (0.28) (0.63)
Net income (loss) per share of common stock, diluted $ (0.05) $ (0.23) $ (0.64)
Weighted average number of common shares outstanding, basic 8,662,671 8,612,986 8,732,849 8,591,663
Weighted average number of common shares outstanding, diluted 8,662,671 8,927,060 8,732,849 8,591,663
[1] Depreciation expense of $7,021 and $12,482 was reclassified as continuing operations in the three and six months ended June 30, 2025, respectively, and is therefore no longer reflected in discontinued operations.
[2] Depreciation expense of $7,021 and $12,482 was reclassified as continuing operations in the three and six months ended June 30, 2025, respectively, and is therefore no longer reflected in discontinued operations.
[3] For the three and six months ended June 30, 2026, other expense included interest expense, share of losses from equity method investments and loss on disposal of property and equipment, offset by interest income. For the three months ended June 30, 2025, other expense included interest expense and share of losses from equity method investments. For the six months ended June 30, 2025, other expense included interest expense and share of losses from equity method investments, offset by interest income and gain on disposal of property and equipment.